> ## Content Index
> Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Concord Biotech Moat Analysis: Score & Risks
- URL: https://www.moatmarginresearch.com/concord-biotech-moat/
- Published: 2026-08-16T17:42:28.000Z
- Updated: 2026-08-22T05:13:17.000Z
- Author: A K Karthikeyan
- Tags: First-pass note, Coverage

Moat Note · First-pass

## Concord Biotech Ltd.

A first-pass moat teardown of Concord Biotech Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

**Moat & Margin**16 Aug 2026 First-pass · \~3 min

5.51 / 10

NARROW → WIDEProcess/Data-led

First-pass narrow-to-wide read — primary edge in Cost Advantage. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Concord Biotech Ltd. scores **5.51** on MoatSCORE 6.0 — a narrow-to-wide moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown 

## Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome.

D3Cost Advantage6.5

M · Mechanism✓ Verified verbatim

“Our strong product portfolio leverages niche expertise and backward integration for Key Starting Materials (KSMs), ensuring efficiency and quality.”

**Concord Biotech Ltd.** · Annual Report · p.12

D6Efficient Scale6

M · Mechanism✓ Verified verbatim

“This expansion aligns with our R&D priorities, where we are developing niche products with complex processes and limited competition.”

**Concord Biotech Ltd.** · Earnings Call · p.4

D1Network Effects5.7

M · Mechanism✓ Verified verbatim

“We supply formulations primarily in India through government and corporate hospitals, while in the US and emerging markets in Asia, Africa, and Latin America, we rely on distributor collaborations.”

**Concord Biotech Ltd.** · Annual Report · p.12

D5Intangible Assets5.5

M · Mechanism✓ Verified verbatim

“We have a dedicated intellectual property team responsible for filing patents in both the Indian and overseas markets.”

**Concord Biotech Ltd.** · Annual Report · p.36

D4Price Discretion5.2

M · Mechanism✓ Verified verbatim

“The factors mentioned above were largely beyond our control and were not related to lower demand, loss of market share or pricing pressure.”

**Concord Biotech Ltd.** · Earnings Call · p.4

D2Switching Costs5

M · Mechanism✓ Verified verbatim

“our customers have begun the qualification process for the Limbasi facility, allowing us to serve them from this unit as well”

**Concord Biotech Ltd.** · Earnings Call · p.3

D7Counter-PositioningExcluded—

Excluded for this archetype.

D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate 

## The barrier gate — first-pass

Replication — can a rival copy it?6.5

How hard it is for a rival to copy the edge (first-pass estimate).

Bypass — can a rival route around it?6.0

How easily a rival can route around the edge (first-pass estimate).

Effective barrier 6 — at or above 6, consistent with a narrow-to-wide read. First-pass estimate.

What would change our mind

1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band.
3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.

**Where this note fits.** This company is one of **509 Indian companies** we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).